Stover EH, Baco MB, Cohen O, et al. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019;17(11):2281-2293. doi:10.1158/1541-7786.MCR-18-1243Google ScholarPubMedDOI
Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905. doi:10.1038/nature08822Google ScholarPubMedDOI
Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108-12. doi:10.1038/nature08460Google ScholarPubMedDOI
Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6(6):565-76. doi:10.1016/j.ccr.2004.10.014Google ScholarPubMedDOI
Wei G, Margolin AA, Haery L, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21(4):547-62. doi:10.1016/j.ccr.2012.02.028Google ScholarPubMedDOI
Rosenbluh J, Nijhawan D, Cox AG, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-73. doi:10.1016/j.cell.2012.11.026Google ScholarPubMedDOI
Moody SE, Schinzel AC, Singh S, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 2015;34(16):2061-71. doi:10.1038/onc.2014.153Google ScholarPubMedDOI
Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377. doi:10.1038/ncomms7377Google ScholarPubMedDOI
Ramanathan A, Schreiber SL. Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci U S A. 2009;106(52):22229-32. doi:10.1073/pnas.0912074106Google ScholarPubMedDOI